Table 1.
Baseline characteristics
| Age (years) | 66.7 ± 11.4 |
| Men, n (%) | 81 (77.1) |
| Aetiology, n (%) | |
| CM ischaemic | 66 (62.9) |
| CM hypertensive | 4 (3.8) |
| CM dilated | 35 (33.3) |
| NYHA functional class, n (%) | |
| I | 9 (8.6) |
| II | 77 (73.3) |
| III | 18 (17.1) |
| IV | 1 (1) |
| Hypertension, n (%) | 72 (68.6) |
| Dyslipidaemia, n (%) | 72 (68.6) |
| Prior admission for acute heart failure, n (%) | 54 (51.4) |
| Left ventricular ejection fraction (%) | 30 (25–35) (25–35) |
| Heart rate (bpm) | 65 (60–73) |
| Systolic blood pressure (mmHg) | 115 (107–130) |
| Diastolic blood pressure (mmHg) | 70 (62–78) |
| Urea (mg/dL) | 45 (32–64)) |
| Creatinine, mg/dL (IQR) | 1.15 (0.95–1.38) |
| Sodium, mmol/L (IQR) | 139 (137–141) |
| Haemoglobin, g/dl (IQR) | 13.8 (12.4–14.8) |
| NT‐proBNP, ng/L (IQR) | 925 (374–1700) |
| eGFR, m/min/m2 (IQR) | 64 (50–82) |
| α‐EP, pg/mL (IQR) | 582 (160–772) |
| γ‐EP, pg/mL (IQR) | 101 (37–287) |
| sNEP, pg/mL (IQR) | 222 (124–820) |
| Δα‐EP, units (IQR) | 9.3 (−34–44) |
| Δγ‐EP, units (IQR) | −3 (−46–18.9) |
| ΔsNEP, units (IQR) | 0 (−16.4–157) |
| Treatments | |
| Furosemide, n (%) | 67 (63.8) |
| Torasemide, n (%) | 15 (14.3) |
| Antialdosteronic, n (%) | 91 (86.7) |
| Beta blockers, n (%) | 101 (96.2) |
| Digoxin, n (%) | 13 (12.4) |
| Statin, n (%) | 71 (67.6) |
| Acetylsalicylic acid, n (%) | 55 (52.4) |
| Nitrates, n (%) | 15 (14.3) |
| Anticoagulants, n (%) | 55 (52.4) |
| Initial daily dose Sac/Val 24/26 mg, n (%) | 67 (63.8) |
| Initial daily dose Sac/Val 49/51 mg, n (%) | 38 (36.2) |
Values are expressed as mean ± SE or median (IQR).
CM, cardiomyopathy; EP, endorphin; eGFR, glomerular filtration rate; NEP, neprilysin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptides; NYHA, New York Heart Association; sNEP, soluble neprilysin.